Targeting Metabolic Vulnerabilities in Glioblastoma: a Framework for Multi-node Combination Therapy

Area of Science:

• Oncology
• Metabolic Pathways
• Cancer Therapeutics

Background:

• Glioblastoma (GBM) presents a poor prognosis with standard treatments.
• Targeted metabolic therapy is being explored as an adjuvant treatment for GBM.

Purpose of the Study:

• To review the rationale for metabolic therapy in GBM.
• To identify resistance mechanisms to metabolic therapies.
• To explore synergistic combination strategies for metabolic therapy in GBM.

Main Methods:

• Literature review of preclinical and clinical studies on metabolic therapy in GBM.
• Analysis of metabolic pathways critical for GBM cell survival and proliferation.
• Evaluation of resistance mechanisms and combination strategies.

Main Results:

• Individual targeting of metabolic enzymes (glycolysis, glutaminolysis, lipid metabolism, etc.) shows promise in preclinical studies.
• GBM cells develop resistance to monotherapy by utilizing alternative metabolic pathways.
• Combination metabolic therapies targeting multiple nodes synergistically inhibit tumor growth and bypass resistance.

Conclusions:

• Metabolic monotherapy has limited success in GBM due to resistance.
• Synergistic combination metabolic therapies are more promising for overcoming resistance.
• Combination regimens delivered with standard care may improve patient outcomes, warranting larger clinical trials.